Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Medline Industries, Inc., a leading name in the medical sector, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1910, the company has established itself within the medical, precision, and optical instruments industry, focusing on the production and distribution of high-quality medical supplies and equipment.
Medline's core offerings include surgical instruments, wound care products, and infection prevention solutions, all designed to enhance patient care and operational efficiency in healthcare settings. The company is recognised for its commitment to innovation and quality, positioning itself as a trusted partner for healthcare providers. With a strong market presence and a reputation for excellence, Medline continues to achieve significant milestones, reinforcing its status as a leader in the medical supply industry.
+34 vs industry average
Medline Industries’s score of 66 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
Medline Industries's latest reported emissions for 2025 were approximately 7.77 billion kg CO2e. This includes about 151.65 million kg CO2e from Scope 1, approximately 136.80 million kg CO2e from Scope 2, and around 7.48 billion kg CO2e from Scope 3 emissions.
In 2024, Medline Industries reported total emissions of approximately 5.09 billion kg CO2e, comprising around 133.23 million kg CO2e for Scope 1, approximately 141.26 million kg CO2e for Scope 2 (market-based), and about 4.81 billion kg CO2e for Scope 3.
For 2023, Medline Industries reported total emissions of approximately 7.28 billion kg CO2e. This consisted of around 173.84 million kg CO2e from Scope 1, about 131.90 million kg CO2e from Scope 2, and approximately 6.97 billion kg CO2e from Scope 3.
Medline Industries has set ambitious climate commitments, including net-zero targets and absolute emission reductions. The company aims for near-term and long-term net-zero emission scenarios for Scope 1 and Scope 2 by 2030 and 2050, respectively. From a 2023 baseline, Medline Industries is committed to reducing its Scope 1 emissions by 30% by 2030 and its Scope 2 emissions by 30% by 2030. Furthermore, Medline Industries Ltd (a related organization) is committed to achieving Net Zero emissions by 2050. This entity projects a 42% absolute reduction in total Scope 1 and Scope 2 carbon emissions to 63 tonnes CO2e by 2030, from a 2022 baseline. It also projects a 25% absolute reduction in Scope 3 carbon emissions (limited to five sub-categories) to 513 tonnes CO2e by 2030, also from a 2022 baseline.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more